ARID1A and cancer: In this study, a drug-sensitivity screen in ARID1A-deficient cancer cells identified unique hits: PRIMA-1 and APR-246; both of which inhibit the activity of the antioxidant metabolite glutathione (GSH) by covalent binding to thiols.